Acute myeloid leukaemia (AML) is a complex and aggressive haematological malignancy that arises from the clonal proliferation of myeloid precursors. It is typified by a marked heterogeneity in ...

1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...

Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based ...

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has recently provided an update on its Phase 3 ...

Despite the development of allogeneic stem-cell transplant (allo-SCT) and novel therapies, outcomes in patients with relapsed ...

Figure 1: FISH of the sex chromosomes was carried out with the probe sets for the X centromere (CEPX – green) and Y centromere (CEPY – red). Karyotype analysis was performed on a bone marrow sample.

AML = Acute myeloid leukemia; CK = Complex karyotype; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organization for Research and Treatment of Cancer; GIMEMA = Italian Group for Adult ...

Reply to: “Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials” and “Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for ...